Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
LXRX Stock Chart & Stats
$1.71
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.71
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.32 - $1.83
Previous CloseN/A
Volume2.02M
Average Volume (3M)3.06M
Market Cap
$724.49M
Enterprise Value$742.46M
Total Cash (Recent Filing)$96.23M
Total Debt (Recent Filing)$62.24M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Apr 30, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding423,680,600
10 Day Avg. Volume2,841,724
30 Day Avg. Volume3,062,283
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue14.91
Enterprise Value/Gross Profit15.08
Enterprise Value/Ebitda-17.40
Forecast
1Y Price Target
$3.78Price Target Upside121.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$20.96M
Bulls Say, Bears Say
Bulls Say
Financial Runway And Program FundingA strong cash balance that supports operations into 2026 reduces immediate financing pressure and enables continued investment in late-stage clinical programs and regulatory activities.
Hypertrophic Cardiomyopathy Clinical ProgressAdvancement of the SONATA pivotal trial for sotagliflozin with enrollment progressing strengthens the prospect of clinical readouts that could support a first-in-class therapy and expand market opportunity.
Partnership Potential For PilavapadinFavorable End-of-Phase-2 feedback and reduced development risk for pilavapadin improve the likelihood of a licensing or partnership deal that could deliver upfront payments and shared development resources.
Bears Say
Dependence On Partners And Approvals For RevenueCommercial and clinical progress depends on regulatory approvals and partner actions, exposing future revenues to external execution risk and variable timing.
Regulatory And Trial Execution RiskCritical regulatory milestones and pivotal trial outcomes carry elevated execution risk, where adverse findings or additional agency requirements could delay or derail approval plans.
Safety Data UncertaintyPending independent study results on drug exposure and ketoacidosis create uncertainty that could influence regulatory reviewers and complicate any resubmission strategy.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.32 and its highest was $1.83 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $724.49M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 51 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Mar 05, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.069 by $0.029.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.03.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 423,680,600 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.069. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.78 (121.05% Upside)
$3.78 (121.05% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 143.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
365.94%
12-Months-Change
Fundamentals
Return on Equity
-41.94%
Trailing 12-Months
Asset Growth
-38.01%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong program-level progress and meaningful financial discipline: multiple regulatory and clinical catalysts are in motion (Sonata enrollment, potential Zynquista resubmission, pilovapitan Phase III readiness, LX9851 milestones), operating expenses and losses were substantially reduced, and the company strengthened its cash position post-period. Offsetting risks include reliance on third-party STENO-1 data for Zynquista, modest INPEFA sales, a reduced year-end cash balance prior to the subsequent raise, and the need to partner to advance pilovapitan into Phase III. On balance, the positive pipeline and financial improvements materially outweigh the remaining execution and external-data risks.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$3.78
▲(121.05% Upside)
Technical Analysis
Ownership Overview
22.77% Insiders
7.70% Mutual Funds
44.93% Other Institutional Investors
22.12% Public Companies and
Individual Investors